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Mechanistic basis of L-lactate transport
in the SLC16 solute carrier family
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In human and other mammalian cells, transport of L-lactate across plasma membranes is
mainly catalyzed by monocarboxylate transporters (MCTs) of the SLC16 solute carrier family.
MCTs play an important role in cancer metabolism and are promising targets for tumor
treatment. Here, we report the crystal structures of an SLC16 family homologue with two
different bound ligands at 2.54 and 2.69 Å resolution. The structures show the transporter in
the pharmacologically relevant outward-open conformation. Structural information together
with a detailed structure-based analysis of the transport function provide important insights
into the molecular working mechanisms of ligand binding and L-lactate transport.
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L-lactate is an important metabolite in health and disease
1. Its
stereoselective transport across plasma membranes is mainly
catalyzed by monocarboxylate transporters (MCTs) of the
SLC16 solute carrier family2. MCTs are predicted to adopt a
protein fold that is characteristic for members of the major
facilitator superfamily (MFS), which contain 12 transmembrane
helices (TMs) arranged in two six-helix bundles. The bundles are
connected by a long intracellular loop connecting TM6 and TM7,
and related to each other by a pseudo-two-fold symmetry axis
that is perpendicular to the membrane plane and along the
substrate translocation pathway. As for other MFS transporters,
the N- and C-termini are located intracellularly2. In TM8 an
arginine residue is conserved in most SLC16 family members and
proposed to be involved in binding of the carboxylate group of
monocarboxylates3,4. Among the 14 mammalian SLC16 family
members, MCT1-4 have been extensively studied and were
identiﬁed as L-lactate:proton symporters2. An extracellular histi-
dine residue is involved in pH regulation of MCT4 activity5. The
unglycosylated MCT1-4 form heterodimers with the ancillary
glycoproteins basigin (CD147) or embigin (GP70), which belong
to the immunoglobulin superfamily and are responsible for
proper trafﬁcking to the plasma membrane6,7. However, they do
not seem to be a prerequisite for transport function8. MCT1-4
exhibit a broad substrate speciﬁcity and are also involved in the
transport of other monocarboxylic metabolites, e.g., pyruvate,
ketone bodies and speciﬁc drugs2. Other members of the
SLC16 solute carrier family encode high-afﬁnity thyroid hormone
(MCT8, SLC16A2) or aromatic amino acid (MCT10, SLC16A10)
transporters, which mediate facilitated transport in contrast to
proton-coupled transport9. While MCT1 (SLC16A1) is ubiqui-
tously expressed, MCT2 (SLC16A7) is mainly found in the liver,
kidney, testis, and in the brain2. MCT2 has a higher afﬁnity for
L-lactate (Km ~0.7 mM) than MCT1 (Km 3–5 mM) and both are
responsible for the uptake of L-lactate into cells2. MCT3
(SLC16A8; Km ~ 6 mM10) is only expressed in the retinal pigment
epithelium and the choroid plexus epithelia, where it serves as
an L-lactate exporter. MCT4 (SLC16A3), which is strongly over-
expressed in highly glycolytic and anaerobic tissues, has a low
afﬁnity for L-lactate (Km 20–35 mM) and is responsible for
L-lactate export2.
MCT1 (SLC16A1) and MCT4 (SLC16A3) are important in
cancer metabolism. Certain tumor cells exhibit high glycolytic
activity to cover the demand of ATP even under aerobic condi-
tions (“Warburg effect”11). The glycolytic phenotype is main-
tained by transporting produced L-lactate out of the cell by
MCT4. In cancer tissue, the acidiﬁcation of the extracellular
microenvironment resulting from co-transported protons is
beneﬁcial for angiogenesis, tumor cell proliferation, invasion and
metastasis11. L-lactate that is exported by MCT4 serves as fuel
for proliferating cancer cells, which import L-lactate by over-
expressed MCT112. Consequently, inhibition of MCT1 and
MCT4 is a promising strategy for treating certain cancer types.
In contrast to MCT1, no selective high-afﬁnity inhibitor of
MCT4 is available13,14.
For the understanding of the molecular working mechanisms
of L-lactate transporters such as MCT1 and MCT4, detailed
structural information is indispensable. Furthermore, high-
resolution structures are an important prerequisite for homol-
ogy modeling and structure-based design of speciﬁc L-lactate
transport inhibitors. Due to the lack of experimentally derived
structures, the design of potent and highly selective inhibitors has
been limited as well as the possibility to perform reliable ligand
docking in silico.
Here, we present the structures of an L-lactate transporter.
Two crystal structures were determined in the presence of the
monocarboxylates thiosalicylate and L-lactate at 2.54 and 2.69 Å
resolution. This bacterial L-lactate transporter (SfMCT) shares
signiﬁcant amino acid sequence identity with human MCT1 and
MCT4. Importantly, the structures show SfMCT in an outward-
open conformation. This conformational state with bound
monocarboxylates is of high pharmacological relevance for the
design of L-lactate transport inhibitors using SfMCT-based
homology models of human MCT1 and MCT4. Furthermore,
we performed structure-function studies to characterize substrate
speciﬁcity and transport, and the substrate-binding site of
SfMCT. The presented crystal structures and functional data
provide important insights into the working mechanism of
SLC16 solute carrier transporters at the molecular level.
Results
Functional characterization of SfMCT. We have identiﬁed a
transporter from Syntrophobacter fumaroxidans (SfMCT) that
shares 25 and 27% amino acid sequence identity, and 51 and
57% sequence similarity with the human SLC16 family L-lactate
transporters MCT1 and MCT4. The transport function of SfMCT
was assessed by uptake of [14C]L-lactate into SfMCT expressing
E. coli JA20215 (Supplementary Fig. 1a). SfMCT transports
L-lactate with an average Km of 233 ± 22 μM (Fig. 1a). To deter-
mine the substrate speciﬁcity of SfMCT, we measured the ability
of physiologically relevant mono-, di- and tricarboxylates at
1 mM concentration to compete with [14C]L-lactate uptake
(Fig. 1b, Supplementary Fig. 2). Among the tested linear unsub-
stituted monocarboxylates, only propionate and butyrate sig-
niﬁcantly reduced [14C]L-lactate uptake (Fig. 1b) without being
transported (Supplementary Fig. 1b). This indicates that besides a
carboxylate group, an aliphatic chain consisting of at least three
carbon atoms is required for signiﬁcant competition. L-lactate, a
chiral, α-hydroxyl substituted propionate, revealed the strongest
competition among all tested physiologically relevant compounds
and its D-isomer. Like MCT416, SfMCT has a clearly higher
speciﬁcity for the α-hydroxyl monocarboxylate L-lactate than for
the α-keto monocarboxylate pyruvate, which decreased the
transport by only ~33% (Fig. 1b). SfMCT does not transport
pyruvate as shown by the presented uptake experiment using
radiolabeled pyruvate (Supplementary Fig. 1b). Positively charged
amino groups are not tolerated at the α-carbon atom as indicated
by the absence of any competition of [14C]L-lactate uptake by
L- and D-alanine. The monocarboxylic ketone bodies ((R)-3-
hydroxybutyrate (3-HBA) and acetoacetate (ACAC)), the dicar-
boxylates oxalate and malonate as well as the tricarboxylate
citrate reduced the [14C]L-lactate uptake by only 5–14% (Fig. 1b).
Comparison of the [14C]L-lactate uptake competition by butyrate
and the butyrate-derived monocarboxylic ketone bodies (i.e., 3-
HBA and ACAC) demonstrates that hydroxyl or oxo groups are
not tolerated at the β-carbon atom. SfMCT has a higher speciﬁ-
city for the dicarboxylate fumarate and its oxidized form succi-
nate than for the shorter dicarboxylates oxalate and malonate.
The uptake of [14C]L-lactate was completely abolished by 20 µM
of the protonophore carbonyl cyanide 3-chlorophenylhydrazone
(CCCP) (Fig. 1b), while the addition of 20 µM valinomycin had
no effect on the transport (Supplementary Fig. 1c). The transport
of [14C]L-lactate decreased with increasing pH values of the
extracellular medium (Supplementary Fig. 1d). To determine if
SfMCT is a proton-coupled L-lactate transporter, we studied
the transport process using a micro pH electrode-based transport
assay17,18, where the electrode measures changes of the extra-
cellular pH of a bacterial suspension. Addition of L-lactate to a
suspension containing SfMCT-expressing E. coli JA202 resulted
in an immediate pH increase (Supplementary Fig. 1e), although
the injected L-lactate solution had a lower pH value than the
bacterial suspension (L-lactate pH 6.5 vs bacterial suspension
pH 6.7). Therefore, the observed pH increase reﬂects L-lactate
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transport induced removal of protons from the extracellular
solution. Addition of L-lactate to a suspension of vector-
transformed bacteria induced a signiﬁcantly slower and lower
pH increase. These results demonstrate that L-lactate transport is
proton-coupled and thus depends on a transmembrane proton
gradient as observed for other L-lactate-transporting SLC16
family members2. Based on the obtained functional data (Fig. 1
and Supplementary Fig. 1a–e), SfMCT is a proton-coupled,
L-lactate speciﬁc transporter.
Overall structure of SfMCT. The structure of SfMCT was solved
at 2.54 Å resolution by single-wavelength dispersion (SAD)
phasing from thiomersal-derivatized crystals (Supplementary
Table 1). The quality of the obtained density map can be assessed
in Fig. 2a. The correct register of the built model was conﬁrmed
by the anomalous difference densities of selenium atoms obtained
of selenomethionine substituted SfMCT crystals (Supplementary
Table 1 and Supplementary Fig. 3a). Crystals contain two SfMCT
molecules in the asymmetric unit (Supplementary Fig. 4) that can
be superimposed with a root-mean-square deviation of 0.261 Å
(Supplementary Fig. 3b). SfMCT consists of 12 TMs with TM1-6
and TM7-12 arranged in an N- and C-terminal six-helix bundle.
The bundles are related to each other by a pseudo-twofold
symmetry axis, which is characteristic for the canonical MFS
fold19,20, and they can be superimposed with a root-mean-square
deviation of 3.45 Å over 179 Cα atoms. The structure shows
SfMCT in an outward-open conformation with a central, conical
cavity open to the periplasmic side while the cytoplasmic side of
SfMCT is closed (Fig. 2b, left panel). The SfMCT overall structure
is comparable to those of MFS transporters that were solved in
the same conformation21. The cavity, which is ~20 Å in depth,
is surrounded by TM1, TM2, TM4 and TM5 of the N-terminal
bundle, and TM7, TM8, TM10 and TM11 of the C-terminal
bundle.
Ligand-binding pocket description. One molecule of the
monocarboxylic ligand thiosalicylate (TSA), which is produced
in situ during ethylmercury TSA derivatization of SfMCT crystals
for phase determination, was found bound to SfMCT (Figs 2b
and 3a–c; see also Supplementary Fig. 5a,b for electron density
and omit maps). With an average inhibition constant (Ki) of
120 μM (Fig. 3d), SfMCT has a higher afﬁnity for TSA than for
its transported substrate L-lactate (Km= 233 μM) (Fig. 1a). In
contrast to L-lactate, TSA is not transported by SfMCT as
determined by a micro pH electrode-based transport assay.
Addition of TSA adjusted at pH 6.5 to suspensions of SfMCT-
expressing or vector-transformed E. coli JA202 adjusted at pH 6.7
resulted in a decrease of the pH of the extracellular medium that
recovered over time (Supplementary Fig. 1f). Thus, TSA did not
lead to a net pH increase as observed for the transported L-lactate
(Supplementary Fig. 1e) and previously for proton-coupled sugar
transport through LacY17. Speciﬁc SfMCT residues interact
through ionic, hydrogen bond and hydrophobic interactions
with TSA constituting the SfMCT ligand-binding site (Fig. 3b, c).
The carboxylate group of TSA interacts with the hydroxyl group
of Y119 (TM4) and the Nη nitrogen atoms of the guanidinium
group of R280 (TM8) (Fig. 3b, c). This positively charged residue
is conserved in TM8 of most SLC16 family members3,4. L145
(TM5) and F335 (TM10) form an ~8 Å wide conﬁnement that
accommodates and orients the carboxylate group of TSA for
proper binding to Y119 (TM4) and R280 (TM8). The thiol group
of TSA is in hydrogen bonding distance to the hydroxyl group of
Y331 (TM10) and 3.5 Å from the isobutyl group of L28 (TM1).
These two residues trap TSA by partly obstructing the ligand-
binding site (Fig. 4a, left panel). The van der Waals pore diameter
along the substrate translocation pathway increases towards the
periplasmic side of the protein as expected for an outward-open
conformation (Fig. 4b). The side chains of F359 (TM11) and
C362 (TM11) are within a distance of <4 Å from the benzene ring
of TSA interacting via hydrophobic interactions. The binding of
TSA demonstrates that residues from the N- and C-terminal
parts of SfMCT are involved in ligand-binding interactions. To
understand the binding mechanism of L-lactate that bound to
the puriﬁed, detergent-solubilized transporter with a Kd of 2.84 ±
0.15 mM (Supplementary Fig. 6a), we co-crystallized SfMCT with
its transported substrate. Two molecules of L-lactate (i.e., Lac1
and Lac2) were found in the binding pocket (Fig. 5a–c; see also
Supplementary Fig. 5c,d for electron density and omit maps). The
carboxylate group of Lac1 interacts with the Nη nitrogen atoms
of the guanidinium group of R280 (TM8), while the hydroxyl
group is hydrogen bonded to the hydroxyl group of Y119 (TM4)
(Fig. 5b, c). Furthermore, the carboxylate group of Lac1 is in
hydrogen bonding distance to the hydroxyl group of Lac2. As
observed for TSA, the Lac1 carboxylate group is sandwiched in
the conﬁnement formed by the side chains of L145 (TM5) and
F335 (TM10). The phenyl-ring of F359 (TM11) points towards
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Fig. 1 Functional characterization of SfMCT. a Concentration dependence of SfMCT-mediated [14C]L-lactate uptake into E. coli JA20215. A representative
saturation curve with Michaelis–Menten equation ﬁt is shown. Data are represented as mean ± SEM from triplicates. An average Km of 233 ± 22 μM was
calculated from three independent saturation experiments, each in triplicate. b Determination of the substrate speciﬁcity of SfMCT by [14C]L-lactate
transport competition assay (1 mM ﬁnal concentration). Molecular structures of the used physiologically relevant compounds are shown in Supplementary
Fig. 2. Residual uptake in the presence of competitor is normalized with respect to control samples without competitor (ctrl). Ketone bodies (R)-3-
hydroxybutyrate and acetoacetate are abbreviated by 3-HBA and ACAC, respectively. Proton-dependence of the uptake was shown by 20 μM of carbonyl
cyanide 3-chlorophenylhydrazone (CCCP). Thiosalicylate is abbreviated by TSA. Data are represented as mean ± SEM from three independent
experiments, each in triplicate. If not visible, error bars are smaller than symbols. Source data are provided as a Source Data ﬁle
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Fig. 3 Binding pocket of SfMCT with bound TSA. a Overall structure of SfMCT in the outward-open conformation viewed in the plane of the membrane
with indicated TSA (black) and binding site residues (cyan). b Binding mechanism of TSA to SfMCT. Residues within a distance of 4 Å from TSA, N276 and
the peptide backbone of V142 are displayed as ball-and-stick model and are highlighted in cyan. c Two-dimensional schematic representation of key
residues that are involved in TSA-binding. Distances in (b, c) are given in Ångström (Å). d Ki determination of wild-type (WT) and Y331F SfMCT for TSA.
The determined Ki values are 120 μM (95% conﬁdence interval: 109–133 μM) for WT and 1384 μM (95% conﬁdence interval: 1245–1539 μM) for Y331F.
Data are represented as mean ± SEM from three independent experiments, each in triplicate. Source data are provided as a Source Data ﬁle
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Fig. 2 Electron density and overall structure of SfMCT. a Electron density map from the SfMCT crystal structure. A view of the ﬁnal 2Fo-Fc electron density
map of TM12 of SfMCT (colored in blue and contoured at 1.5 σ) is shown. The anomalous difference electron density (contoured at 3 σ) of one Hg atom is
shown in orange. The SfMCT structure is displayed as stick model. b Overall structure of SfMCT in the outward-open conformation viewed in the plane
of the membrane (left) and from the periplasm (right). One molecule of bound thiosalicylate is shown in yellow as space-ﬁlling model. The asterisk
highlights the central, conical cavity that is open to the periplasmic side and the dark grey, vertical broken line the pseudo-twofold symmetry axis of SfMCT.
The N- and C-termini are labeled. Parts of the termini and of the loops connecting TM1 and TM2, TM5 and TM6 as well as TM6 and TM7 could not
be traced and are indicated by broken lines. Models are colored based on rainbow coloring scheme
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-10566-6
4 NATURE COMMUNICATIONS |         (2019) 10:2649 | https://doi.org/10.1038/s41467-019-10566-6 | www.nature.com/naturecommunications
a b
TSA-bound
SfMCT
L-lactate-bound
SfMCT
Periplasm
Substrate
binding region
Pore radius (Å)
D
is
ta
nc
e 
al
on
g 
tra
ns
po
rt 
pa
th
 (Å
) 20
15
10
5
0
–5
–10
–15
–20
543210
TSA-bound structure
L-lactate-bound structure
Y331
L28
Y331L28
Fig. 4 Analysis of van der Waals surfaces of SfMCT structures. a Cut-open views of structures of TSA (left) and L-lactate (right) bound SfMCT in the
outward-open conformation. Insets show the obstruction site (red ellipse) between L28 (TM1) and Y331 (TM10) as well as the bound substrates TSA and
L-lactate (insets). In the L-lactate bound SfMCT structure L28 (TM1) is rotated away from the obstruction site. b The van der Waals pore radius as a
function of the distance along the transport path was computed using HOLE50. Plots represent the pore radii values of TSA (black) and L-lactate (red)
bound SfMCT. The triangle highlights the obstruction site between L28 (TM1) and Y331 (TM10)
2.7
2.9
R280
N276
Y331
F335
L145
Y119
L28
F359
V142(O)
N276(O) Nε
Nη1
Nη2
3.0
3.4
3.0
2.5
2.8
WT L2
8A
Y1
19
A
Y1
19
F
L1
45
A
N2
76
A
R2
80
A
Y3
31
A
Y3
31
F
F3
35
A
F3
59
A
C3
62
A
0
25
50
75
100
125
150
Up
ta
ke
 o
f [
14
C]
L-
la
ct
at
e 
(%
)
ba
Out
In
B
in
di
ng
 s
ite
re
gi
on
c d
Lac2
Lac1
C362
2.6
2.7
R280
Y331
F335
Y119
L145
F359
Nε N
N N+
O
HO
HO
HO
OH
–
O O
O
–
Nη1Nη2
2.5 2.8
Lac2
Lac1
2.6
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of the role of TSA- and L-lactate binding residues on [14C]L-lactate transport using an in vivo uptake assay. Transport activities of SfMCT mutants were
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Source data are provided as a Source Data ﬁle
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Lac1 with a distance of 3.4 Å between the C4 carbon atom of the
benzene ring and the methyl-group of Lac1. Most residues
involved in ligand binding adopt similar conformations in the
SfMCT structures with bound TSA and L-lactate. The exception
is L28 (TM1), which is rotated away from the central cavity in
the presence of L-lactate (Fig. 4a, right panel and Fig. 5b). This
removes the binding site obstruction observed in the presence of
TSA and generates space to accommodate Lac2 (Fig. 4). To
investigate the mechanisms of TSA binding and L-lactate trans-
port, we measured [14C]L-lactate uptake into bacteria expressing
SfMCT versions harboring mutations of residues in the identiﬁed
ligand-binding sites (Figs 3b and 5b). All variants were expressed
as judged from Western blot analysis (Supplementary Fig. 7a).
The replacement of R280 (TM8), which is involved in ligand
binding (Figs 3b and 5b), by alanine (R280A) completely abol-
ished L-lactate binding (Supplementary Fig. 6b) and [14C]L-lactate
transport (Fig. 5d) as observed for MCT14. N276 is conserved in
TM8 of bacterial SLC16 homologues (Supplementary Fig. 8a). It
interacts with R280 (TM8) via hydrogen bonds between its side
chain amide group and the backbone carbonyl oxygen atom
(N276(O) (TM8)), and the Nε and Nη1 nitrogen atoms of the
guanidinium group of R280 (TM8) (Figs 3b and 5b, and Sup-
plementary Fig. 8b). Furthermore, the Nη2 nitrogen atom of the
guanidinium group of R280 (TM8) is hydrogen bonded to the
backbone carbonyl oxygen of V142 (V142(O) (TM5)). This allows
precise orientation of R280 (TM8) for proper interaction with
the carboxyl group of ligands (Figs 3b and 5b). Replacing N276
(TM8) by alanine (N276A) led to an inactive transporter (Fig. 5d).
Y119 (TM4) is involved in the binding of the carboxylate
group of TSA (Fig. 3) and the hydroxyl group of Lac1 (Fig. 5).
Neither Y119A nor the conservative mutation Y119F showed any
[14C]L-lactate transport, which is in line with our observation that
the hydroxyl group of L-lactate interacts with the hydroxyl group
of Y119 (TM4) (Fig. 5b, c). L145 (TM5) and F335 (TM10) are
close to R280 (TM8), and we have shown that they conﬁne the
substrate-binding site. Replacing these residues by alanine affected
[14C]L-lactate transport: L145A (TM5) signiﬁcantly reduced the
uptake by 86%, while replacing the phenyl-ring of F335 (TM10)
by alanine increased transport activity indicating that F335 might
sterically interfere with substrate binding to assure substrate spe-
ciﬁcity. The alanine mutant Y331A is not functional but the
conservative mutant Y331F transports [14C]L-lactate as wild-type
(WT). While the hydroxyl group of Y331 (TM10) is not crucial for
[14C]L-lactate transport, it is essential for TSA binding (Fig. 3).
Y331F has a much lower afﬁnity for TSA (Ki= 1384 μM) com-
pared to WT SfMCT (Ki= 120 μM) (Fig. 3d). Substitution of
F359 and C362 (TM11) by alanine led to complete transport
abrogation (F359A) and a low residual transport activity (26%,
C362A), respectively (Fig. 5d).
Proton binding site of SfMCT and pH dependence of L-lactate
transport. L-lactate transport through SfMCT depends on a
transmembrane proton gradient (Fig. 1b and Supplementary
Fig. 1d). Since protons are co-transported with L-lactate (Sup-
plementary Fig. 1e), a binding site for the protons must be present
in SfMCT. In MCT4 a histidine residue that is accessible from the
extracellular side is involved in the pH-dependent regulation of
the transport activity5. In SfMCT there are only two histidine
residues. H250 is intriguing, because it is located at the end of a
transmembrane domain (TM7) near the periplasm (Fig. 6a,b)
where it can bind protons from the extracellular space. The sec-
ond histidine residue is found intracellularly at the second to last
position of the C-terminus (H411), thus not being exposed to the
periplasm. Due to the pKa value of histidine, H250 (TM7) could
act as a titratable proton acceptor under physiological conditions
as observed for MCT45. The side chain of H250 (TM7) is exposed
to the central cavity and oriented by a hydrogen bond between its
imidazole ring and the hydroxyl group of Y383 (loop between
TM11 and TM12), which is conserved in SfMCT and MCT1-4
(Fig. 6b and Supplementary Fig. 9). Positively (R256 (TM7) and
K377 (TM11)) and negatively (D257 (TM7) and D378 (TM11))
charged residues are arranged in an alternating fashion above
H250 (TM7) and Y383 (loop between TM11 and TM12), and
point towards the central cavity that is open to the periplasm. To
investigate the role of H250 (TM7) and the other residues of
the potential proton-binding site (Fig. 6a, b), we measured the
transport function of corresponding mutants. All variants were
expressed as judged from Western blot analysis (Supplementary
Fig. 7b). While [14C]L-lactate transport through H250A was sig-
niﬁcantly reduced to only ~12%, D257A, D378A and Y383A did
not transport any substrate (Fig. 6c). Removal of the positively
charged amino acids R256A and K377A led to an increased
negative electrostatic surface charge in the potential proton
binding site (Supplementary Fig. 10). [14C]L-lactate transport
through these mutants was comparable with transport through
WT SfMCT (Fig. 6c). The negative charge density was further
increased by replacing R256 (TM7) and K377 (TM11) by
aspartate (i.e., R256D and K377D). [14C]L-lactate transport
through R256D was ~2.5 fold increased, while uptake through
K377D was similar to WT SfMCT. The observed increased
transport through R256D cannot be attributed to a higher
expression level (Supplementary Fig. 7b). Based on the observed
efﬁcient L-lactate transport of the R256A/D and K377A/D
mutants, we conclude that the positive charges of R256 (TM7)
and K377 (TM11) are not crucial for initial binding of the
negatively charged L-lactate substrate on the extracellular surface
of SfMCT and its transfer towards the substrate-binding site.
On the other hand, the fact that removal of negatively charged
residues (D257A and D378A) resulted in inactive transporters
suggests their involvement in proton binding. Next, we replaced
the titratable H250 (TM7) by a phenylalanine to introduce a non-
titratable side chain of comparable steric demand that cannot be
involved in hydrogen bond interactions. This H250F mutation
resulted in an inactive transporter. A possible explanation for this
observation is that phenylalanine cannot be oriented appro-
priately due to the missing hydrogen bond interaction with the
hydroxyl group of Y383 (loop between TM11 and TM12). This
interaction with the imidazole ring of H250 (TM7) is functionally
important as shown by the strongly reduced transport activity
of the conservative mutant Y383F (Fig. 6c).
We investigated the pH-dependence of [14C]L-lactate transport
through WT SfMCT, the fully functional alanine mutants
(R256A and K377A) and the charge-inversion mutant R256D,
which revealed a signiﬁcantly higher activity than WT SfMCT.
All tested mutants and WT SfMCT showed higher transport
activities at lower than at higher pH-values as expected for a
proton-dependent transporter (Fig. 6d). This supports our
previous observations of proton-coupled L-lactate transport
(Supplementary Fig. 1e) and the completely abolished substrate
transport by CCCP (Fig. 1b). Under basic conditions R256D had
a similar uptake as WT SfMCT under acidic conditions (Fig. 6e).
Transport activities of R256A, R256D and K377A were
signiﬁcantly higher at alkaline pH-values than for the virtually
inactive WT SfMCT (Fig. 6d).
Discussion
We have presented the structures of an L-lactate transporter
(SfMCT) with two different bound ligands. Both structures
show SfMCT in the pharmacologically relevant outward-open
conformation, which is an essential prerequisite for the design of
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L-lactate transport inhibitors using SfMCT structure-based
homology models of human MCT1 and MCT4. Homology
models of rat MCT1 and MCT4 have been previously
published7,22,23. These models are based on the inward-open
structure of the glycerol-3-phosphate:phosphate antiporter
GlpT19, which belongs to a different MFS subfamily (i.e., the
organophosphate:phosphate antiporter family), and GlpT shares
low sequence identity with rat MCT1 and MCT4 (i.e., 18.5 and
17.3%, respectively). Importantly, functionally relevant residues
are not conserved between GlpT and MCTs. Secondary structure
analysis of the outward-open rat MCT1 homology model23
revealed that many transmembrane spanning domains were
fragmented consisting of relatively short α-helices, and a con-
siderable amount of hydrogen-bonded turns, bends and 310-
helices24–26 (Supplementary Fig. 11a). Such a high fraction of
non-α-helical structural elements is not observed in transmem-
brane domains of prokaryotic and eukaryotic MFS transporters.
Furthermore, TM2 is distorted and no α-helical structure was
detected in the analysis (Supplementary Fig. 11a). Overlaying the
rat MCT1 model with our experimental SfMCT structure resulted
in a high root-mean-square deviation of 6.44 Å (over 1882 atoms)
and revealed that the topologies are roughly comparable, but the
secondary structure is signiﬁcantly different. Furthermore, the
structural alignment has uncovered signiﬁcant differences
between the locations and orientations of functionally relevant
key residues, which are responsible for the binding of TSA and
L-lactate (Supplementary Fig. 11b). In summary, incorrect and
unprecise locations/orientations of functional key residues in the
rat MCT1 homology model preclude the reliable use of structure-
based applications, e.g., molecular dynamics simulations and
structure-based drug design.
Our ligand-bound SfMCT structures and functional studies
provide a framework for understanding the molecular working
mechanisms of substrate binding of SLC16 transporters. SfMCT
shares signiﬁcant amino acid sequence identity and similarity
with human MCT1 and MCT4. It is a valid model to study their
transport function since SfMCT also transports L-lactate in a
stereospeciﬁc and proton-dependent manner. Furthermore, the
afﬁnity of SfMCT for L-lactate is higher than for pyruvate and
monocarboxylic ketone bodies as observed for MCT42. Therefore,
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Fig. 6 Proton binding site of SfMCT and pH dependence of L-lactate transport. a Overall structure of SfMCT in the outward-open conformation viewed in
the plane of the membrane with indicated proton binding site residues (cyan). b Structure of the proton binding site region comprising H250 (TM7), R256
(TM7), D257 (TM7), K377 (TM11), D378 (TM11) and Y383 (loop between TM11 and TM12). c Determination of the role of potential proton binding site
residues on [14C]L-lactate transport using an in vivo uptake assay. Transport activities of SfMCT mutants were normalized with respect to wild-type (WT).
Data are represented as mean ± SEM from three independent experiments, each in triplicate. d pH-dependence of proton binding site mutants. Each trace
represents the average of three independent experiments that were individually normalized by ﬁtting a sigmoidal curve to the data points and setting
the ﬁtted upper plateau value to 100% [14C]L-lactate uptake (see Methods section for details on the normalization procedure). Data are represented as
mean ± SEM from three independent experiments, each in triplicate. If not visible, error bars are smaller than symbols. e Comparison of [14C]L-lactate
transport through WT SfMCT at pH 6, and WT and R256D at pH 8.5. The uptake through WT at pH 6, and WT and R256 at pH 8.5 were normalized with
respect to the [14C]L-lactate uptake through WT at pH 6. Data are represented as mean ± SEM from three independent experiments, each in triplicate.
Source data are provided as a Source Data ﬁle
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the oxidation state and geometry of the α-carbon atom (e.g., sp3
for L-lactate vs sp2 hybridization for pyruvate) affects the sub-
strate speciﬁcity of SfMCT similar to mammalian MCT1 and
MCT4. Since SfMCT does not tolerate an amino group at the
α-carbon atom of a substrate, this excludes amino acids and their
derivatives as substrates. Therefore, SfMCT does not represent
an optimal model for the well-studied SLC16 thyroid hormone
(MCT8) and aromatic amino acid (MCT10) transporters2. These
two SLC16 family members are also different from MCT1-4
because they are not associated to ancillary proteins9. The
structures of TSA- and L-lactate-bound SfMCT demonstrate that
the conserved arginine residue in TM8 is essential for mono-
carboxylate binding. This key residue is also crucial for function
in certain mammalian SLC16 family members4,27. Not even a
conservative mutation to lysine, which is a primary amine and
shorter than arginine, was able to maintain MCT1 function22.
Mutation of this arginine to glutamine resulted in an inactive
version of human MCT1, which is associated with ketoacidosis28.
The resulting non-functional MCT1 cannot bind and transport
monocarboxylic ketone bodies into target cells, since the posi-
tively charged guanidinium group is essential for substrate
binding. However, not only the presence of the guanidinium
group of R280 is important for substrate binding. The correct
positioning of R280 (TM8), which is maintained by hydrogen
bonds to the side chain of the conserved N276 (TM8) and to
peptide backbone atoms (Supplementary Fig. 8b), is also a pre-
requisite for the efﬁcient binding of the substrate carboxylate
group (Figs 3 and 5). Based on our structures and functional data,
Y331 (TM10) is located at a strategic position and it seems to be
involved in ligand-binding speciﬁcity. This is highlighted by the
fact that removal of its hydroxyl group drastically reduced the
afﬁnity for TSA binding, while L-lactate was still properly trans-
ported by Y331F. This mutant reﬂects the situation in human
MCT1 (Supplementary Fig. 9) that efﬁciently transports L-lactate
into cells. However, replacing the aromatic side chain by alanine
resulted in an inactive SfMCT transporter similar to mammalian
MCTs4,29. Interestingly, a phenylalanine to cysteine exchange at
the corresponding position in MCT1 resulted in a gain of func-
tion mutant. This mutant did not transport L-lactate, but cata-
lyzed the transport of the slightly larger substrate mevalonate,
which is not transported by WT MCT130. The conﬁnement
formed by L145 (TM5) and F335 (TM10) accommodates the
carboxylate groups of TSA and L-lactate. Together with Y119
(TM4), these residues seem to be involved in a mechanism to
regulate the speciﬁcity and transport efﬁciency of L-lactate in
SfMCT. Replacing sterically demanding residues (e.g., leucine and
phenylalanine) generates more space for the carboxylate to
reorient such that bulkier substrates are bound. This has been
shown when the phenyl-ring of F335 (i.e., F335A) was removed
resulting in a higher speciﬁcity for the bulkier ketone body ACAC
(Supplementary Fig. 1g).
The presented functional characterization has shown that
L-lactate transport through SfMCT is coupled to the co-transport
of protons, which requires proton binding. We have identiﬁed a
proton binding site consisting of residues at the periplasmic ends
of TM7 (H250, R256 and D257) and TM11 (D378), and in the
loop between TM11 and TM12 (Y383) (Fig. 6a, b). The two
negatively charged aspartate residues (D257 (TM7) and D378
(TM11)) might act as antennas for protons from the periplasm,
and thus they are essential for transport as shown experimentally
(Fig. 6c). Their relevance in proton-dependent L-lactate trans-
porters is underlined by their conservation in SfMCT and human
MCT2-4 (Supplementary Fig. 9). The response of [14C]L-lactate
transport on extracellular pH changes was affected by the posi-
tively charged amino acid R256 (TM7) and substitutions of this
residue. Its charge-neutralization (R256A) or -inversion (R256D)
rendered the corresponding SfMCT mutants active even at basic
pH values, where proton-dependent transporters are usually
inactive. The higher activity of these two SfMCT mutants under
alkaline conditions suggests that the coupling between L-lactate
and proton transport is altered upon removal of the positive
charge at this position. The increased negative charge density of
the proton binding site associated with R256A or R256D raises
the afﬁnity for positively charged protons such that a lower
extracellular proton concentration (i.e., basic pH-values) is suf-
ﬁcient for driving efﬁcient transport. This is highlighted by the
fact that R256D showed similar uptake under basic pH conditions
as WT SfMCT under acidic pH conditions (Fig. 6e). However,
simply increasing the negative charge density of the proton
binding site is not sufﬁcient to improve activity as shown by the
unaffected transport through K377D (Supplementary Fig. 10g
and Fig. 6c). Therefore, the correct position of the additional
negative charge is crucial as demonstrated by the effect of the
charge-inversion R256D. Under basic conditions the positively
charged residues R256 (TM7) and K377 (TM11) might interact
with the two negatively charged aspartate residues via unresolved
water molecules. Consequently, protonation of antenna residues
would lead to an increase of the local positive charge density. In
the absence of negatively charged amino acids (i.e., D257A and
D378A), the resulting net positive charge density of R256 (TM7)
and K377 (TM11) might reduce the accessibility of H250 (TM7)
for protonation due to electrostatic repulsion. In WT SfMCT,
protons that were captured by the proton antennas (i.e., D257
(TM7) and D378 (TM11)) might be transferred to H250 (TM7),
which can sense extracellular pH due to its appropriate location
near the periplasm (Fig. 6a, b). In MCT4, an essential histidine
residue involved in pH regulation of transport activity was
identiﬁed in a similar region like the proton binding site in
SfMCT5. We propose that protonation of the imidazole ring
leads to breaking of the weak hydrogen bond between the con-
served and for [14C]L-lactate transport essential Y383 (Fig. 6b and
Supplementary Fig. 9) and H250. This would allow adopting
other conformers of the side chains of H250 and Y383, thus
allowing proton transfer towards the cytoplasmic part of SfMCT.
However, transfer of captured protons from the initial proton
antennas to H250 might also occur via water molecules in the
form of hydronium intermediates, which could not be resolved
in the presented structures at given resolutions.
In summary, we reported two structures of the bacterial
SLC16 homologue SfMCT in complex with the monocarboxylates
TSA and L-lactate. The presented structural and functional data
have provided important insights into the molecular working
mechanism of L-lactate transporters.
Methods
Cloning. The gene of a major facilitator superfamily-type transporter from Syn-
trophobacter fumaroxidans (SfMCT, UniProt ID code A0LNN5) was synthesized
codon-optimized for expression in E. coli (GenScript, Supplementary Table 2).
SfMCT was ligated into the pZUDF21-rbs-3C-10His vector31 using 5’-HindIII
and 3’-XhoI restriction sites for overexpression, or into the pEXT20 vector32
using 5’-EcoRI and 3’-XhoI restriction sites for functional studies. The resulting
constructs (pZUDF21-rbs-SfMCT-3C-10His and pEXT20-SfMCT-3C-10His)
contained a C-terminal human rhinovirus 3C (HRV3C) protease cleavage site
and a decahistidine-tag (His-tag). Site-directed mutagenesis was done using a
proofreading polymerase (KAPA HiFi DNA Polymerase, KAPABiosystems) and
the primers listed in Supplementary Table 3. DNA sequences were veriﬁed by gene
sequencing (Microsynth).
Expression and membrane preparation. SfMCT was expressed in E. coli BL21
(DE3)pLysS grown at 37 °C in Luria Bertani (LB) medium supplemented with
antibiotics (100 μg/ml ampicillin and 36 μg/ml chloramphenicol) at 180 r.p.m. in
an incubator shaker (Multitron, Infors HT). Protein expression was induced at
OD600 ~0.9 by the addition of isopropyl-β-D-thiogalactopyranoside (IPTG) to a
ﬁnal concentration of 0.25 mM. After four hours, cells were harvested by cen-
trifugation (10,000 × g, 6 min, 4 °C), resuspended in lysis buffer (45 mM Tris-HCl
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(pH 8), 450 mM NaCl, 4 °C) and pelleted again (10,000 × g, 25 min, 4 °C). The ﬁnal
cell pellet was resuspended in lysis buffer. Bacteria were disrupted using an M-110P
Microﬂuidizer (Microﬂuidics) operated at 1,500 bar during six passages. Unlyzed
bacteria were removed by low-speed centrifugation (10,000 × g, 10 min, 4 °C).
The supernatant was subjected to ultracentrifugation (200,000 × g, 90 min, 4 °C) to
isolate bacterial membranes. The resulting pellet was resuspended in lysis buffer,
homogenized and subjected to ultracentrifugation (200,000 × g, 90 min, 4 °C).
Finally, membranes were resuspended and homogenized in buffer (20 mM Tris-
HCl (pH 8), 150 mM NaCl, 10% (v/v) glycerol) at 100 mg/ml and stored at −80 °C.
Expression of L-selenomethionine-labeled SfMCT. For the expression of L-
selenomethionine-labeled SfMCT (SfMCTSeMet), an overnight culture of E. coli
BL21(DE3)pLysS transformed with pZUDF21-rbs-SfMCT-3C-10His was grown at
37 °C in LB medium supplemented with antibiotics (100 μg/ml ampicillin and
36 μg/ml chloramphenicol) at 180 r.p.m in an incubator shaker (Multitron, Infors
HT). The culture was pelleted (10,000 × g, 6 min, 4 °C) and resuspended in minimal
medium (33.7 mM Na2HPO4, 22 mM KH2PO4, 9 mM NaCl, 10 mM (NH4)2SO4,
1 mM MgSO4, 0.1 mM CaCl2, 20 mM D-glucose, 1 mg/l thiamine-hydrochloride
and 1 μM FeSO4). Washed bacteria were diluted 1:100 in minimal medium
supplemented with 100 μg/ml ampicillin and grown to OD600 ~0.6 at 37 °C and
180 r.p.m. in an incubator shaker (Multitron, Infors HT). An L-amino acid mixture
(lysine (100 mg/l), phenylalanine (100 mg/l), threonine (100 mg/l), isoleucine
(50 mg/l), leucine (50 mg/l), valine (50 mg/l)) and L-selenomethionine (60 mg/l)
were added to the culture to inhibit the L-methionine synthesis pathway. The
culture was incubated for 30 min at 37 °C before inducing SfMCTSeMet expression
by addition of IPTG to a ﬁnal concentration of 0.25 mM. Further processing of
the expression culture, membrane isolation and puriﬁcation followed the same
procedure as described for unlabeled SfMCT.
Puriﬁcation. All puriﬁcation steps were performed at 4 °C. Membranes were
solubilized by gentle stirring in solubilization buffer (20 mM Tris-HCl (pH 8), 150
mM NaCl, 10% (v/v) glycerol, 4% (w/v) n-nonyl β-D-glucopyranoside (NG, Glycon
Biochemicals GmbH)) for 2 h. Subsequently, solubilized membranes were clariﬁed
by ultracentrifugation (200,000 × g, 30 min, 4 °C). The supernatant was diluted with
an equal volume of detergent-free solubilization buffer supplemented with 5 mM L-
histidine. Solubilized membranes were then incubated with nickel-nitrilotriacetate
resin (Ni-NTA; ProteinIso) (1 ml resin bed volume for solubilized membranes
from one liter expression culture) under gentle stirring. After 2 h, the resin was
transferred into a column using a peristaltic pump operated at 4 ml/min. The resin
was washed with 25 column volumes of washing buffer (20 mM Tris-HCl (pH 8),
150 mM NaCl, 5% (v/v) glycerol, 5 mM L-histidine, 0.4% (w/v) NG). SfMCT was
eluted from the column by incubating the resin with His-tagged HRV3C on a
rotational shaker for ~16 h. Co-eluted HRV3C and undigested SfMCT were
removed by an additional Ni-NTA puriﬁcation.
Crystallization. Puriﬁed SfMCT or SfMCTSeMet was concentrated to 8 mg/ml
using a 50,000 Da molecular weight cutoff concentration device (SARTORIUS
Stedim Biotech, Vivaspin 2). Aggregated protein was removed by ultra-
centrifugation (150,000 × g, 30 min, 4 °C). The protein was crystallized in the
sitting-drop vapor-diffusion method by mixing concentrated protein with reservoir
solution (50 mM HEPES-NaOH (pH 7), 5 mM ZnBr2, 30% (v/v) Jeffamine ED-
2003) using a Mosquito Crystal Robot (TTP Labtech). Crystals appeared after one
day of incubation at 18 °C and reached maximal size after one week. Before X-ray
analysis, crystals were ﬂash frozen in liquid nitrogen. For mercury derivatization,
crystals were incubated in reservoir solution supplemented with 0.5 mM ethyl-
mercury thiosalicylate and 0.5% (w/v) NG. For co-crystallization with L-lactate,
all puriﬁcation buffers were supplemented with 10 mM sodium L-lactate.
Data collection and structure determination. All data sets were collected on
frozen crystals at the X06SA (PXI) beamline of the Swiss Light Source (Paul
Scherrer Institute, Villigen, Switzerland) using an EIGER 16M detector (Dectris).
Three data sets were collected at low-dose per frame and high-redundancy for
phasing. For SeMet two data sets and for the L-lactate structure four data sets from
different crystals were collected. The data sets were indexed and integrated with
XDS33, then merged using BLEND34 of the CCP4 program suite35 without trun-
cation of the resolution. The high-resolution data set was collected from a single
crystal at high-dose per frame (Supplementary Table 1). The data were indexed and
integrated with XDS33 without truncation of the resolution. Scaling and averaging
of symmetry-related intensities for all data sets were performed by aP_scale36 with
truncation of the data at the best high-resolution along h, k or l axis determined by
AIMLESS37. Due to the anisotropic nature of the diffraction data, the STARANISO
software (http://staraniso.globalphasing.org/) was applied. This program performs
an anisotropic cut-off of merged intensity data to perform Bayesian estimation of
structure amplitudes and to apply an anisotropic correction to the data. For
phasing and generation of an initial SfMCT model, the SAD method was applied
using the CRANK238 automated structure solution pipeline running SHELX39/D40,
REFMAC541, Parrot42 and Buccaneer43 in the CCP4 program suite35. In CRANK2,
phases were extended to the diffraction limit of the high-resolution data set. To
obtain a complete structure, iterative reﬁnement and model building were
performed by phenix.reﬁne44 and Coot45 using the high-resolution data set,
respectively. The structure of SfMCT with bound L-lactate was obtained by
molecular replacement with Phaser46 using the SfMCT structure with bound TSA
as search model. The ﬁnal structures were obtained after multiple rounds of model
building with Coot45 and reﬁnement with phenix.reﬁne44. For all the reﬁnements,
XYZ coordinates, individual B-factors, occupancies and TLS strategies were
applied. The TLS groups were automatically assigned using Phenix. Full data
collection, processing and reﬁnement statistics can be found in Supplementary
Table 1. Figures representing structural information were prepared using Chi-
mera47 or PyMol (The PyMol Molecular Graphics System; Schrödinger).
Calculation of electrostatic surface potentials of SfMCT variants. The
electrostatic surface potentials of SfMCT and SfMCT variants were calculated using
the APBS plugin of PyMol. SfMCT variants were generated in silico using the
mutagenesis tool of PyMol. The resulting APBS-calculated electrostatic surface
potentials were presented using PyMol.
Uptake experiments. Overnight precultures of E. coli JA202 (MC4100 glcA::cat
lldP::kan)15, a strain that lacks the endogenous L-lactate transporters LldP and
GlcA, transformed with empty vector (pEXT20-3C-10His) or plasmids carrying
SfMCT and SfMCT mutants (pEXT20-SfMCT-3C-10His) were diluted 1:200 into
LB-medium supplemented with 100 μg/ml ampicillin. The cultures were grown
at 37 °C and 180 r.p.m. in an incubator shaker (Multitron, Infors HT). Protein
expression was induced at OD600 ~0.5 by addition of IPTG to a ﬁnal concentration
of 0.25 mM. After 4 h, bacteria were pelleted (5,200 × g, 10 min, room temperature)
and resuspended in uptake buffer (20 mM Bis-Tris propane-HCl (pH 6.7), 250 mM
KCl) to a bacteria density of OD600 12. Transport experiments were done in a
reaction volume of 50 µl that included 20 µl of cell-suspension (2.4 × 108 bacteria),
10 µl of substrate master mix (67 µM sodium L-lactate spiked with [14 C(U)] L-
lactic acid sodium salt ([14C]L-lactate, American Radiolabeled Chemicals) to a
speciﬁc activity of 0.15 Ci/mmol) and 20 µl of competitor solution. Furthermore,
[3-3 H] propionic acid sodium salt ([3H]propionate, American Radiolabeled
Chemicals, speciﬁc activity 30 Ci/mmol), n-[2,3-3 H] butyric acid sodium salt ([3H]
butyrate, American Radiolabeled Chemicals, speciﬁc activity 120 Ci/mmol), and
[1–14 C] pyruvic acid sodium salt ([14C]pyruvate, speciﬁc activity 0.055 Ci/mmol
American Radiolabeled Chemicals) were also used for transport experiments. For
Km determination, [14C]L-lactate was diluted to a speciﬁc activity of 0.0008 Ci/
mmol. Uptake experiments were performed in 2 ml reaction tubes (Eppendorf) at
30 °C under agitation (1,000 r.p.m., Thermomixer compact, Eppendorf). Reactions
were stopped after 30 min by addition of 900 μl stop buffer (20 mM HEPES-NaOH
(pH 7.5), 150 mM NaCl). Bacteria were immediately pelleted by centrifugation
(21,000 × g, 4 min, room temperature) and washed two times with 900 μl stop
buffer. Finally, bacteria were lyzed in 50 μl 5% (w/v) sodium dodecylsulfate and
transferred into a white 96-well plate (Optiplate, PerkinElmer). 150 µl of scintil-
lation cocktail (MicroScint 40, PerkinElmer) were added before measuring each
reaction for 2 min with a scintillation counter (TopCount NXT, PerkinElmer). For
data analysis, the signal of the empty vector was subtracted from the transporter
signal. The pH-dependence of [14C]L-lactate transport through SfMCT variants
was measured in Bis-Tris propane based uptake buffers (20 mM Bis-Tris propane-
HCl, 250 mM KCl) that were adjusted to the desired pH values using HCl. pH-
dependence curves were individually processed by ﬁtting a sigmoidal curve to the
raw data of each individual experiment, i.e., counts-per-minute (cpm) vs pH. Cpm
values of each experiment were normalized with respect to the determined upper
plateau value, i.e., the ﬁtted upper plateau value corresponds to 100%. The arith-
metic average of three independent experiments was calculated. Three independent
and normalized pH-dependence curves were then averaged. For data analysis
Prism6 (GraphPad Software) was used. The expression of SfMCT variants in E. coli
JA202 (MC4100 glcA::cat lldP::kan)15 was veriﬁed by Western blotting. Equal
amounts of bacteria expressing SfMCT variants were loaded on 14% SDS/poly-
acrylamide gels. His-tagged transporters were detected using an anti-His5 (Qiagen,
catalogue number 34660, primary antibody) at a dilution of 1:3,000 and a goat anti-
mouse IgG (H+ L) HRP conjugate antibody (Biorad, catalogue number 172-1011,
secondary antibody) at a dilution of 1:2,500.
Micro pH electrode-based transport measurements. A measuring set up as
previously reported18 was used for micro pH electrode-based transport measure-
ments. SfMCT was expressed in E. coli JA202 (MC4100 glcA::cat lldP::kan)15
as described for uptake experiments. After expression, bacteria were pelleted
(5,200 × g, 10 min, room temperature), washed twice in assay solution (250 mM
KCl, 1 mM MgSO4, 2 mM CaCl2; 5,200 × g, 10 min, room temperature) and ﬁnally
resuspended in assay solution to a bacterial density of OD600 15. Compounds that
were assayed for proton-coupled transport were dissolved in assay solution and the
pH was adjusted to 6.5. 800 µl of bacteria suspension were transferred into a 2 ml
reaction tube (Eppendorf) and the pH value of the bacterial suspension (extra-
cellular medium) was measured using a micro pH electrode with integrated tem-
perature sensor (InLab Micro Pro, Mettler Toledo) under constant stirring. The pH
of the bacterial suspension was adjusted to pH 6.7 using potassium hydroxide and
hydrochloric acid. The SevenCompact pH-meter (Mettler Toledo), together with
LabX direct pH 2.3 software (Mettler Toledo), were used for automatic recording in
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15 s intervals. Measurements were initiated by adding 10 mM of the corresponding
compound to the bacterial suspension. All experiments were performed at 24 °C.
Microscale thermophoresis binding assay. Binding of L-lactate to puriﬁed,
detergent-solubilized SfMCT and SfMCT-R280A was measured with the micro-
scale thermophoresis (MST) binding assay using the Monolith NT.115 MST device
(NanoTemper technologies). His-tagged SfMCT and SfMCT-R280A were afﬁnity-
puriﬁed in n-dodecyl β-D-maltopyranoside (DDM, Glycon Biochemicals GmbH) as
described in the Puriﬁcation section. The protein was eluted from the Ni-NTA
column using an imidazole-containing buffer (20 mM Bis-Tris propane-HCl
(pH 8), 150 mM NaCl, 400 mM imidazole, 0.03% (w/v) DDM) followed by buffer
exchange into MST buffer (20 mM Bis-Tris propane-HCl (pH 8), 150 mM NaCl,
0.03% (w/v) DDM) using a desalting column (Zeba spin desalting columns 7k
MWCO, Thermo Scientiﬁc). Proteins were labelled using the His-tag labeling kit
(NanoTemper technologies) as described by the manufacturer with minor mod-
iﬁcations. Instead of using phosphate-buffered saline supplemented with Tween 20
for the dilution of the protein and the labeling dye, MST buffer was used. A binding
experiment consisted of 16 samples (20 μl), which contained 50 nM labeled SfMCT
or SfMCT-R280A, and L-lactate at a concentration from 7.6 μM to 250 mM. A
500 mM stock solution of L-lactate was prepared in MST buffer. The samples were
loaded into coated glass capillaries (Premium Capillaries, NanoTemper technolo-
gies). The MST measurements were performed under ambient conditions using
medium MST power and 20% LED excitation power. The Kd value was calculated
using the mass action equation (NanoTemper technologies). The average Kd value
was determined from 5 independent experiments.
Sequence alignment and sequence logo generation. Amino acid sequence
alignment was performed with Clustal Omega48. The UniProt ID codes of SfMCT,
human MCT1, human MCT2, human MCT3 and human MCT4 are A0LNN5,
P53985, O60669, O95907 and O15427, respectively. The sequence logo repre-
sentation of the region close (+/−11 amino acids) to N276 of SfMCT was com-
puted using a multiple sequence alignment of SfMCT and bacterial homologues.
Bacterial homologues of SfMCT were identiﬁed by searching the bacterial target
database of UniProt Knowledgebase on ExPASy using the BLAST algorithm
(https://web.expasy.org/blast/) with the SfMCT amino acid sequence (UniProt ID
A0LNN5) as template. The ﬁrst 50 sequences were selected and aligned with
Clustal Omega using the BLOSUM 62 substitution matrix48. The sequence logo
was computed using WebLogo49.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Atomic coordinates for the TSA and L-lactate bound crystal structures of SfMCT have
been deposited in the Protein Data Bank under accession numbers 6G9X (TSA) and
6HCL (L-lactate). The source data underlying Figs 1a, b, 3d, 5d, 6c–e, Supplementary
Figs 1, 6 and 7 are provided as a Source Data ﬁle. Other data are available from the
corresponding author upon reasonable request.
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